Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 in Subjects With Moderate to Severe Asthma
NCT07372287Phase 3Recruiting
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing CM326 with Placebo (2 arms). Primary endpoint: Annualized rate of severe asthma exacerbations at 52 weeks. Started Jan 2026; status: recruiting.
02
Drugs
CM326
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07372287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07372287.